Central venous access related adverse events after trabectedin infusions in soft tissue sarcoma patients; experience and management in a nationwide multi-center study

BACKGROUND: Trabectedin has shown efficacy against soft tissue sarcomas (STS) and has manageable toxicity. Trabectedin is administered through central venous access devices (VAD), such as subcutaneous ports with tunneled catheters, Hickman catheters and PICC lines. Venous access related adverse even...

Descripción completa

Detalles Bibliográficos
Autores principales: Verboom, Michiel C., Ouwerkerk, Jan, Steeghs, Neeltje, Lutjeboer, Jacob, Martijn Kerst, J., van der Graaf, Winette T. A., Reyners, Anna K. L., Sleijfer, Stefan, Gelderblom, Hans
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5282803/
https://www.ncbi.nlm.nih.gov/pubmed/28163887
http://dx.doi.org/10.1186/s13569-017-0066-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5282803/
https://www.ncbi.nlm.nih.gov/pubmed/28163887
http://dx.doi.org/10.1186/s13569-017-0066-6

Ejemplares similares